Search research articles
Contact Us
Filters
Showing results (111-120 of 129) with videos related to
Page
of 13
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 6, 2025
Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301)
Adi Diab, Paolo A Ascierto, Michele Maio, et al.
Cancer Immunology, Immunotherapy : CII
|
October 13, 2018
Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study
Maria Pia Pistillo, Vincenzo Fontana, Anna Morabito, et al.
Journal for Immunotherapy of Cancer
|
November 16, 2019
The density and spatial tissue distribution of CD8<sup>+</sup> and CD163<sup>+</sup> immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors
Daniela Massi, Eliana Rulli, Mara Cossa, et al.
Frontiers in Immunology
|
March 14, 2018
Corrigendum: Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study
Paola Queirolo, Beatrice Dozin, Anna Morabito, et al.
Frontiers in Immunology
|
April 28, 2017
Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study
Paola Queirolo, Beatrice Dozin, Anna Morabito, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 1, 2022
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated <i>BRAF</i>-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial
Paolo A Ascierto, Mario Mandalà, Pier Francesso Ferrucci, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 24, 2024
Combined immunotherapy in melanoma patients with brain metastases: A multicenter international study
Mario Mandalà, Paul Lorigan, Maria Chiara Sergi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 12, 2025
Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective study
Mario Mandalà, Teresa Amaral, Piotr Rutkowski, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 26, 2023
Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian Melanoma Intergroup
Marco Rubatto, Paolo Fava, Ignazio Stanganelli, et al.
Frontiers in Oncology
|
October 12, 2020
An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival
Francesco Mannavola, Mario Mandala, Annalisa Todisco, et al.
Page
of 13
Search research articles
Search
Showing results (111-120 of 129) with videos related to
Sort By:
Page
of 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 6, 2025
Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301)
Adi Diab, Paolo A Ascierto, Michele Maio, et al.
Cancer Immunology, Immunotherapy : CII
|
October 13, 2018
Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study
Maria Pia Pistillo, Vincenzo Fontana, Anna Morabito, et al.
Journal for Immunotherapy of Cancer
|
November 16, 2019
The density and spatial tissue distribution of CD8<sup>+</sup> and CD163<sup>+</sup> immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors
Daniela Massi, Eliana Rulli, Mara Cossa, et al.
Frontiers in Immunology
|
March 14, 2018
Corrigendum: Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study
Paola Queirolo, Beatrice Dozin, Anna Morabito, et al.
Frontiers in Immunology
|
April 28, 2017
Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study
Paola Queirolo, Beatrice Dozin, Anna Morabito, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 1, 2022
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated <i>BRAF</i>-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial
Paolo A Ascierto, Mario Mandalà, Pier Francesso Ferrucci, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 24, 2024
Combined immunotherapy in melanoma patients with brain metastases: A multicenter international study
Mario Mandalà, Paul Lorigan, Maria Chiara Sergi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 12, 2025
Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective study
Mario Mandalà, Teresa Amaral, Piotr Rutkowski, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 26, 2023
Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian Melanoma Intergroup
Marco Rubatto, Paolo Fava, Ignazio Stanganelli, et al.
Frontiers in Oncology
|
October 12, 2020
An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival
Francesco Mannavola, Mario Mandala, Annalisa Todisco, et al.
Page
of 13